Recent Finacing
Recent Raise
Guard Therapeutics develops RMC-035, a kidney-protective therapeutic for patients undergoing open-heart surgery, currently conducting a global phase 2 (AKITA) trial and preparing phase 3/CMC activities.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
